Pulmodyne and fluidIQ Sign Licensing, Joint R&D Agreement

PRESS RELEASE

INDIANAPOLIS—Global manufacturer and distributor of high-quality airway and respiratory products Pulmodyne Inc. and fluidics-based MedTech company fluidIQ Inc. announced Oct. 7, 2022, a global licensing and joint research and development agreement. Pulmodyne, an Intersurgical company, will license fluidIQ's technology.

"Pulmodyne is thrilled to partner with such a talented group of engineers and designers. We feel our existing expertise, combined with fluidIQ technology, will allow us to bring a host of new patient focused products to the market," said Andrew Shurig, president of Pulmodyne.

"This agreement will allow fluidIQ to license our innovative technology to one of the largest and most respected respiratory and EMS distributors in the world," said Matt Vogelhuber, RPh, CEO of fluidIQ. "Working closely with Pulmodyne, our team of world-class doctors and engineers can more quickly and efficiently respond to unmet medical needs across the United States and internationally."

The companies will co-develop innovative technology for the respiratory and emergency medicine spaces based on fluidIQ's proprietary, fluidics-based platform that enables miniaturization and automation of technology without relying on sensors, electricity or batteries. Fluidics is a science that uses the flows and pressures of fluids or air to control operations normally performed by battery-powered or electronic devices.

The global reach of Pulmodyne and its parent company, Intersurgical, will provide wide access to fluidIQ's innovative technologies. fluidIQ is seeking FDA clearance for its initial product, which is currently not available for sale in the United States or internationally.

Visit www.pulmodyne.com and www.fluidiq.org